NVDA Q3 Earnings Alert: Why our AI stock picker is still holding Nvidia stockRead More

4 big analyst cuts: Ambarella takes a plunge

Published 31/05/2023, 11:32
HIBB
-
AMBA
-
NGMS
-
RAIN
-

By Davit Kirakosyan

Here is your Pro Recap of the biggest analyst cuts you may have missed since yesterday: downgrades at Ambarella, Hibbett Sports, NeoGames, and Rain Therapeutics.

InvestingPro subscribers got this news first. Never miss another market-moving headline.

Ambarella downgraded following disappointing guidance

KeyBanc downgraded Ambarella (NASDAQ:AMBA) to Sector Weight from Overweight following Q1 earnings yesterday.

Shares plunged more than 18% in premarket today after the chipmaker reported a weaker-than-expected outlook for Q2.

KeyBanc mentioned several reasons for the downgrade, including (1) limited design wins in non-China auto despite significant investments in CV, (2) the Continental/Bosch wins have only resulted in limited progress, and (3) the pivot to AI inferencing is concerning as it may distract from achieving greater success in auto with CV3.

Hibbett Sports downgraded at BofA Securities

BofA Securities downgraded Hibbett Sports (NASDAQ:HIBB) to Underperform from Buy and cut its price target to $35.00 from $85.00, citing a "significant slowdown" after the company cut its full-year forecast last week.

Management now expects a full-year profit of $7-$7.75, down from the prior $9.5-$10 forecast. Comparable sales are expected to fall low-single digits.

Despite its cautious outlook for the near future in terms of consumer behavior, BofA Securities are confident that the company is in a strong position to sustain growth and expand its market share in the long run.InvestingPro | Always Know First

2 more downgrades

Macquarie downgraded Neogames (NASDAQ:NGMS) to Neutral from Outperform. The company reported its Q1 results earlier this month, missing revenue expectations.

Roth/MKM downgraded Rain Therapeutics (NASDAQ:RAIN) to Neutral from Buy and cut its price target to $1.20 from $2.00 after the company provided an update on milademetan clinical programs.

The company will suspend enrollment in the ongoing milademetan Phase 2 MANTRA-2 basket trial and has terminated plans for initiation of the Phase 1/2 MANTRA-4 combination trial.

In fast-moving markets, every second counts - and InvestingPro subscribers are always one step ahead with lightning-quick updates.

Start your free 7-day trial now.

InvestingPro | Be The First To Know

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.